Interactions between Droperidol and Strattera

The atomoxetine in Strattera has a major potential interaction with Bipolar Disorder.

Atomoxetine increased the risk of suicidal ideation in pediatric patients with ADHD, and patients should be monitored closely for suicidal thoughts and behavior, clinical worsening, or unusual behavioral changes, especially during initial therapy or dosage changes. Before initiating atomoxetine, patients should be screened for bipolar disorder risk factors, and discontinuation should be considered if treatment-emergent psychotic or manic symptoms occur.

The atomoxetine in Strattera has a moderate potential interaction with Cardiovascular Conditions and Disorders.

Atomoxetine should be used with caution both in patients with conditions that may predispose them to hypotension or abrupt changes in heart rate or blood pressure, and in patients with underlying medical conditions that could be worsened by increases in blood pressure or heart rate, such as hypertension, tachycardia, cardiovascular disease, or cerebrovascular disease. Heart rate and blood pressure should be measured at baseline, following atomoxetine dosage increases, and periodically during therapy to detect clinically important increases.

The atomoxetine in Strattera has a moderate potential interaction with Cerebral Vascular Disorder.

Atomoxetine should be used with caution both in patients with conditions that may predispose them to hypotension or abrupt changes in heart rate or blood pressure, and in patients with underlying medical conditions that could be worsened by increases in blood pressure or heart rate, such as hypertension, tachycardia, cardiovascular disease, or cerebrovascular disease. Heart rate and blood pressure should be measured at baseline, following atomoxetine dosage increases, and periodically during therapy to detect clinically important increases.

The atomoxetine in Strattera has a major potential interaction with Depression.

Atomoxetine increased the risk of suicidal ideation in pediatric patients with ADHD, and patients should be monitored closely for suicidal thoughts and behavior, clinical worsening, or unusual behavioral changes, especially during initial therapy or dosage changes. Before initiating atomoxetine, patients should be screened for bipolar disorder risk factors, and discontinuation should be considered if treatment-emergent psychotic or manic symptoms occur.

droPERidol has a major potential interaction with Electrolyte Abnormalities.

Cases of QT prolongation and/or torsade de pointes have been reported in patients receiving droperidol at doses at or below recommended doses. Extreme caution is recommended when using this agent in patients with risk factors for development of prolonged QT syndrome, such as clinically significant bradycardia, any clinically significant cardiac disease, treatment with Class I and Class III antiarrhythmics, treatment with monoamine oxidase inhibitors (MAOI's), concomitant treatment with other drug products known to prolong the QT interval, and electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs that may cause electrolyte imbalance. It is advisable that all patients undergo a 12-lead ECG prior to administration to determine if a prolonged QT interval (i.e., QTc greater than 440 msec. for males or 450 msec. for females) is present. If there is a prolonged QT interval, droperidol should not be administered.

The atomoxetine in Strattera has a major potential interaction with Glaucoma, Narrow Angle.

The use of atomoxetine is contraindicated in patients with narrow angle glaucoma. In clinical trials, atomoxetine use was associated with an increased risk of mydriasis.

The atomoxetine in Strattera has a major potential interaction with Heart Disease.

Atomoxetine is contraindicated in patients with severe cardiac or vascular disorders whose condition would be expected to deteriorate if they had clinically important increase in blood pressure (e.g., 15 to 20 mmHg) or heart rate (e.g., 20 beats per minute). Atomoxetine generally should not be used in pediatric patients with known serious structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, or other serious cardiac problems, and clinicians should consider not treating adults with clinically significant cardiac abnormalities, due to the risk of sudden death. Carefully assess cardiovascular history and perform physical exam before treatment, conduct further cardiac evaluation when indicated, and stop atomoxetine pending prompt cardiac evaluation if exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease occur.

The atomoxetine in Strattera has a major potential interaction with High Blood Pressure.

CNS stimulants increase blood pressure and heart rate; the use of some agents may be contraindicated in patients with severe/uncontrolled hypertension. Caution should be used when administering to patients with preexisting high blood pressure (even mild hypertension) and other cardiovascular conditions. All patients under treatment should be regularly monitored for potential tachycardia and hypertension.

droPERidol has a major potential interaction with Hypokalemia.

Cases of QT prolongation and/or torsade de pointes have been reported in patients receiving droperidol at doses at or below recommended doses. Extreme caution is recommended when using this agent in patients with risk factors for development of prolonged QT syndrome, such as clinically significant bradycardia, any clinically significant cardiac disease, treatment with Class I and Class III antiarrhythmics, treatment with monoamine oxidase inhibitors (MAOI's), concomitant treatment with other drug products known to prolong the QT interval, and electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs that may cause electrolyte imbalance. It is advisable that all patients undergo a 12-lead ECG prior to administration to determine if a prolonged QT interval (i.e., QTc greater than 440 msec. for males or 450 msec. for females) is present. If there is a prolonged QT interval, droperidol should not be administered.

The atomoxetine in Strattera has a moderate potential interaction with Hypotension.

Atomoxetine should be used with caution both in patients with conditions that may predispose them to hypotension or abrupt changes in heart rate or blood pressure, and in patients with underlying medical conditions that could be worsened by increases in blood pressure or heart rate, such as hypertension, tachycardia, cardiovascular disease, or cerebrovascular disease. Heart rate and blood pressure should be measured at baseline, following atomoxetine dosage increases, and periodically during therapy to detect clinically important increases.

droPERidol has a moderate potential interaction with Liver Disease.

Droperidol should be administered with caution in patients with liver and kidney dysfunction because of the importance of these organs in the metabolism and excretion of drugs.

The atomoxetine in Strattera has a moderate potential interaction with Liver Disease.

Atomoxetine can cause severe liver injury. Atomoxetine exposure is increased in patients with moderate or severe hepatic impairment, and a lower dosage is recommended in these patients. Atomoxetine should be permanently discontinued in patients with jaundice or laboratory evidence of liver injury. Liver enzyme and function tests should be obtained at the first symptom or sign of liver dysfunction.

droPERidol has a major potential interaction with Long QT Syndrome.

Cases of QT prolongation and/or torsade de pointes have been reported in patients receiving droperidol at doses at or below recommended doses. Extreme caution is recommended when using this agent in patients with risk factors for development of prolonged QT syndrome, such as clinically significant bradycardia, any clinically significant cardiac disease, treatment with Class I and Class III antiarrhythmics, treatment with monoamine oxidase inhibitors (MAOI's), concomitant treatment with other drug products known to prolong the QT interval, and electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs that may cause electrolyte imbalance. It is advisable that all patients undergo a 12-lead ECG prior to administration to determine if a prolonged QT interval (i.e., QTc greater than 440 msec. for males or 450 msec. for females) is present. If there is a prolonged QT interval, droperidol should not be administered.

droPERidol has a major potential interaction with Long QT Syndrome.

The use of droperidol is contraindicated in patients with known or suspected QT prolongation (i.e., QTc interval greater than 440 msec. for males or 450 msec. for females), including those patients with congenital long QT syndrome.

droPERidol has a major potential interaction with Magnesium Imbalance.

Cases of QT prolongation and/or torsade de pointes have been reported in patients receiving droperidol at doses at or below recommended doses. Extreme caution is recommended when using this agent in patients with risk factors for development of prolonged QT syndrome, such as clinically significant bradycardia, any clinically significant cardiac disease, treatment with Class I and Class III antiarrhythmics, treatment with monoamine oxidase inhibitors (MAOI's), concomitant treatment with other drug products known to prolong the QT interval, and electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs that may cause electrolyte imbalance. It is advisable that all patients undergo a 12-lead ECG prior to administration to determine if a prolonged QT interval (i.e., QTc greater than 440 msec. for males or 450 msec. for females) is present. If there is a prolonged QT interval, droperidol should not be administered.

The atomoxetine in Strattera has a major potential interaction with Pheochromocytoma.

Atomoxetine is contraindicated in patients with pheochromocytoma or a history of pheochromocytoma. Serious reactions, including elevated blood pressure and tachyarrhythmia, have been reported in patients with pheochromocytoma or a history of pheochromocytoma who received atomoxetine.

droPERidol has a moderate potential interaction with Pheochromocytoma.

Droperidol should be used with caution in patients with diagnosed or suspected pheochromocytoma as severe hypertension and tachycardia have been observed after its administration.

The atomoxetine in Strattera has a major potential interaction with Psychosis.

Atomoxetine increased the risk of suicidal ideation in pediatric patients with ADHD, and patients should be monitored closely for suicidal thoughts and behavior, clinical worsening, or unusual behavioral changes, especially during initial therapy or dosage changes. Before initiating atomoxetine, patients should be screened for bipolar disorder risk factors, and discontinuation should be considered if treatment-emergent psychotic or manic symptoms occur.

droPERidol has a moderate potential interaction with Renal Dysfunction.

Droperidol should be administered with caution in patients with liver and kidney dysfunction because of the importance of these organs in the metabolism and excretion of drugs.